Literature DB >> 30280836

Chitosan-based Nanoparticles in Mucosal Vaccine Delivery.

M Mehrabi1, H Montazeri2, N Mohamadpour Dounighi3,3, A Rashti1, R Vakili-Ghartavol1.   

Abstract

Most infectious diseases are caused by pathogenic infiltrations from the mucosal tract. Nowadays, the use of vaccines has been widely investigated for the prevention of different infectious diseases, infertility, immune disorders, malignancies, and allergies. Broad-spectrum adjuvant substances have been studied for immune system stimulation with a greater efficiency against specific antigens. Various adjuvants have been developed such as inorganic, oil-based, and emulsion adjuvants, bacterial products and their derivatives, cytokines, cytosine-guanine dinucleotide (CpG) motifs, and particulate systems. Mucosal vaccine delivery is an alternative route to induce both humoral and cellular immune responses. Applying nanoparticles in vaccine formulations allows not only improved antigen stability and immunogenicity, but also targeted delivery, and consequently, more specific release of the agent of interest. Chitosan nanoparticles have immunological activity and mucoadhesive properties. They have been used as a mucosal vaccine delivery system for many antigens. This review provides an overview of the recent advances in chitosan nanoparticles as a novel mucosal vaccine delivery system.
Copyright © 2018, Archives of Razi Institute. Published by Kowsar.

Entities:  

Keywords:  Adjuvant; Chitosan Nanoparticle; Mucosal Vaccine Delivery

Mesh:

Substances:

Year:  2018        PMID: 30280836     DOI: 10.22092/ari.2017.109235.1101

Source DB:  PubMed          Journal:  Arch Razi Inst


  4 in total

Review 1.  Multiple Roles of Chitosan in Mucosal Drug Delivery: An Updated Review.

Authors:  Paola Mura; Francesca Maestrelli; Marzia Cirri; Natascia Mennini
Journal:  Mar Drugs       Date:  2022-05-20       Impact factor: 6.085

2.  Simultaneous Intramuscular And Intranasal Administration Of Chitosan Nanoparticles-Adjuvanted Chlamydia Vaccine Elicits Elevated Protective Responses In The Lung.

Authors:  Yumeng Li; Chuan Wang; Zhenjie Sun; Jian Xiao; Xiaoliang Yan; Yuqing Chen; Jian Yu; Yimou Wu
Journal:  Int J Nanomedicine       Date:  2019-10-08

Review 3.  Immunomodulation as a Novel Strategy for Prevention and Treatment of Bordetella spp. Infections.

Authors:  Monica C Gestal; Hannah M Johnson; Eric T Harvill
Journal:  Front Immunol       Date:  2019-12-13       Impact factor: 7.561

Review 4.  How the Lack of Chitosan Characterization Precludes Implementation of the Safe-by-Design Concept.

Authors:  Cíntia Marques; Claudia Som; Mélanie Schmutz; Olga Borges; Gerrit Borchard
Journal:  Front Bioeng Biotechnol       Date:  2020-03-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.